Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa). This prevents the conversion of fibrinogen to fibrin and inhibits clot formation.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
Continuous intravenous infusion: initial bolus 80 units/kg (max 10,000 units) followed by infusion at 18 units/kg/hour (usual adult dose 1,000-2,000 units/hour). For prophylactic use: subcutaneous 5,000 units every 8-12 hours.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
Dose-dependent: 30–60 min after 25 U/kg IV, 60–90 min after 100 U/kg IV, 150 min after 400 U/kg IV. Terminal half-life: ~1.5 h (low dose) to ~5 h (high dose). Context: nonlinear due to saturable clearance mechanisms.
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal (minimal, saturable) and reticuloendothelial system (heparinase). Unchanged heparin: negligible urinary excretion. Metabolites: desulfated heparin via hepatic and extrahepatic heparinase; inactive fragments cleared renally.
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticoagulant
Anticoagulant